United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tokyo, Japan and Cambridge, UK, 06 November 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) has been notified by Pfizer that it has entered a new oral small molecule GLP-1 receptor agonist into a Phase 1 clinical trial. PF-06954522 was discovered by Pfizer scientists during a multi-target research collaboration in which Pfizer had access to Sosei Heptares' proprietary StaR® (stabilized receptor) technology. Pfizer recently detailed the entry of PF-06954522 into its Internal Medicine focused clinical pipeline as part of its Q3 2023 results on 31 October 2023.

Sosei Heptares' Partner, Pfizer, Progresses Its GLP-1 Receptor Agonist PF-06954522 into a Phase 1 Trial

A-Mark Precious Metals

Arch Resources

AdvanSix

Cal-Maine Foods

Civitas Resources

Coterra Energy

Chevron

Dime Community Bank

Freeport-McMoRan

Inter Parfums

Kulicke & Soffa Industries

Nutrien

ONEOK

Pioneer Natural Resources

Star Bulk Carriers

Sociedad Quimica Y Minera De Chile

Tenaris S.A.

On October 25 2023 an on-line edition of Fortune Magazine revealed 100 Fastest Growing Public Companies. My Dogcatcher quest to sniff-out dividend-buys found 57 dividend-paying fast-growers using YCharts 11/1/23 data. The companies featured on the fastest-growing companies list, which ranks companies based on growth in revenue, profits, and stock returns, are worth a combined $4 trillion in market capitalization. 57 dividend yielding stocks highlighted those 100 fastest-growers and ranged 0.04% to 15.8% in annual-yield, while the 100 ranged -73.61% to 122.42% in broker-estimated one-year price-target-upsides by YCharts 11/1/23 reckoning.

9 Ideal November Fortune Fast Growers Out Of 100

Enel Chile

Coca-Cola

A mix of trepidation and optimism permeate the fluctuating U.S. stock market landscape at this time. Consequently, the hunt for stocks to buy for under $100 becomes more of a strategic endeavor.

3 Stocks Priced Under $100 That You Can't Afford to Miss

AT&T

Vici Properties

Verizon

High dividend yield companies are valuable assets for your portfolio, since they are a great way to generate added income, which you can reinvest or use it to pay your bills. In today's article, I will present you with three companies that pay an attractive Dividend Yield, have a relatively low Valuation, and a 24M Beta Factor below 1. Being available for an attractive Valuation and having a Beta Factor below 1, these high dividend yield companies can help reduce your investment portfolio's volatility and risk level.

Seeking High Dividends? 3 Fairly Valued/Undervalued High Dividend Yield Stocks For Your Portfolio

Automatic Data Processing

Albemarle

American Homes 4 Rent

Ares Capital

Alexandria Real Estate Equities

Bristol-Myers

British American Tobacco

Cigna

Cincinnati Financial

Deere & Company

Dollar General

Dick's Sporting Goods

EOG Resources

W.W. Grainger

Hershey

Johnson & Johnson

JPMorgan Chase & Co

KeyCorp

Lennar

Microchip Technology

MPLX

Microsoft

NextEra Energy

NXP Semiconductors

Old Dominion Freight Line

PepsiCo

Procter & Gamble

PulteGroup

Sherwin-Williams

Truist Financial

Target

UnitedHealth Group

Visa

Vale S.A.

This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields just over 3%, we present two other groups of five DGI stocks each, with the goal of moderate to high yields.

5 Relatively Secure And Cheap Dividend Stocks To Invest In - November 2023

Pfizer (NYSE: PFE) reported its Q3 results earlier this week, with revenues missing but earnings beating the street estimates, and we believe that PFE stock has ample

Should You Pick Pfizer Stock At $30?

Baidu

ConocoPhillips

Cisco Systems

LyondellBasell Industries

Stellantis N.V. 

With the major equity indices signaling the possibility of a slowdown – if not an outright downcycle – investors may be better served considering overlooked value stocks. At this moment, I like the idea of self-preservation, meaning that taking on hyped growth names may not be prudent.

Why These 7 Overlooked Value Stocks Could Be Your Golden Opportunity

Pfizer reported an adjusted loss of nearly $1 billion in the third quarter, and recently lowered its forecasts for coronavirus product sales. The company also faces potential sales declines in other blockbusters as they lose exclusivity.

There's a Silver Lining in Pfizer's Dark Cloud. Should You Buy the Stock?

News for Pfizer Stock (PFE)